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Abstract
Purpose Although important for apoptosis, the signaling pathway involving MOAP-1(Modulator of Apoptosis 1), RASSF1A 
(RAS association domain family 1A), and Bax (Bcl-2 associated X protein) is likely to be dysfunctional in many types of 
human cancers due to mechanisms associated with gene mutation and DNA hyper-methylation. The purpose of the present 
study was to assess the potential impact of generating physiologically relevant signaling pathway mediated by MOAP-1, 
Bax, and RASSF1A (MBR) in cancer cells and chemo-drug resistant cancer cells.
Methods The tricistronic expression construct that encodes MOAP-1, Bax, and RASSF1A (MBR) or its mutant, MOAP-
1∆BH3L, Bax and RASSF1A (MBRX) was expressed from an IRES (Internal Ribosome Entry Site)-based tricistronic 
expression vector in human breast cancer cells, including MCF-7, MCF-7-CR (cisplatin resistant) and triple negative breast 
cancer cells, BMET05, for functional characterization through in vitro and in vivo models.
Results Transient expression of MBR potently promoted dose-dependent apoptotic signaling and chemo-sensitization in 
the cancer cells, as evidenced by loss of cell viability, nuclei condensation and Annexin-V positive staining while stable 
expression of MBR in MCF-7 cells significantly reduced the number of MBR stable clone by 86% and the stable clone 
exhibited robust chemo-drug sensitivity. In contrast, MBRX stable clone exhibited chemo-drug resistance while transiently 
over-expressed MOAP-1ΔBH3L inhibited the apoptotic activity of MBR. Moreover, the spheroids derived from the MBR 
stable clone displayed enhanced chemo-sensitivity and apoptotic activity. In mouse xenograft model, the tumors derived 
from MBR stable clone showed relatively high level of tumor growth retardation associated with the increase in apoptotic 
activity, leading to the decreases in both tumor weight and volume.
Conclusions Expression of MBR in cancer cells induces apoptotic cell death with enhanced chemo-sensitization requiring 
the BH3L domain of MOAP-1. In animal model, the expression of MBR significantly reduces the growth of tumors, sug-
gesting that MBR is a potent apoptotic sensitizer with potential therapeutic benefits for cancer treatment.
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PCR  Polymerase chain reaction
SDS-PAGE  Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis
APC  Allophycocyanin
PEI  Polyethylenimine
FACS  Fluorescence-activated cell sorting
NOD SCID  Nonobese diabetic/severe combined 
immunodeficiency
IACUC  Institutional Animal Care and Use Research 
Committee
TUNEL  Terminal deoxynucleotidyl transferase 
dUTP nick end labeling
Introduction
MOAP-1 (Modulator of Apoptosis 1) is a member of the 
PNMA family which consists of at least 15 family members 
that are encoded in human chromosomes, 8, 14, 19, and X 
(Schuller et al. 2005; Pang et al. 2018). Members of the 
PNMA family were reported to be involved in Paraneoplastic 
Disorder (PND) in which a few family members, including 
PNMA 1–3, were found to be aberrantly expressed in a num-
ber of human tumors (Dalmau et al. 1999; Voltz et al. 1999; 
Sahashi et al. 2003). Aberrant expression of PNMA fam-
ily members in tumor cells is likely to be the contributing 
factor that leads to development of PND in which patients 
are often diagnosed with neurodegenerative conditions, 
including paraneoplastic limbic encephalitis, production of 
anti-sera against PNMA1, 2 or 3, and cancer (Barnett et al. 
2001; Rosenfeld et al. 2001; Sahashi et al. 2003; Albert and 
Darnell 2004; Hoffmann et al. 2008). Tissue expression 
studies showed that PNMA family members are normally 
expressed in relatively high levels in human brain and testis 
except MOAP-1, which showed ubiquitous expression with 
high levels of expression in both human brain and heart, 
and lower levels of expression in human skeletal muscle, 
kidney, and pancreas (Tan et al. 2001; Schuller et al. 2005; 
Takaji et al. 2009). CCDC8, another PNMA family mem-
ber, was also reported to exhibit ubiquitous expression in 
many human tissues (Hanson et al. 2011; Pang et al. 2018). 
Although MOAP-1 shares high amino acid sequence homol-
ogy to PNMA family members, anti-sera obtained from 
PND patients were unable to react with MOAP-1, suggesting 
functional divergence among the PNMA family members 
(Rosenfeld et al. 2001).
MOAP-1 was identified through yeast two hybrid screen 
using Bax as bait, and overlapping clones of MOAP-1 con-
taining BH-3 like (BH3L) domain were identified. The 
BH3L domain of MOAP-1 was shown to be required for 
binding to Bax, and MOAP-1 was reported to participate 
in apoptotic signaling by interacting with pro-apoptotic 
Bax, leading to Bax activation and induction of cell death 
through mitochondrial signaling pathway (Tan et al. 2001, 
2005). The BH3L domain of MOAP-1 shares significant 
sequence homology to BH3 domain of pro-death members 
of Bcl-2 family (Tan et al. 2001). Further characterization 
of MOAP-1 showed that the N-terminus of MOAP-1 local-
ized to mitochondria, and over-expressed MOAP-1 exhibited 
both cytosolic and peri-nuclear localization patterns (Tan 
et al. 2005). Furthermore, MOAP-1 knock-down MCF-7 
cells exhibited resistance to multiple apoptotic stimuli, and 
formed large tumors in mice xenograft model, suggesting 
that MOAP-1 functions as tumor suppressor (Tan et al. 2005; 
Law et al. 2015). MOAP-1 has short half-life which is regu-
lated by the ubiquitin–proteasome pathway (Fu et al. 2007; 
Lee et al. 2009; Huang et al. 2012).
Recent evidence showed that MOAP-1 and RASSF1A are 
associated with TNFR in the presence of TNF stimulation, 
leading to activation of a signaling cascade in which acti-
vated MOAP-1 promotes Bax translocation to mitochondria, 
resulting in the release of cytochrome C from mitochon-
dria (Tan et al. 2005; Vos et al. 2006; Fu et al. 2007; Foley 
et al. 2008). RASSF1A is encoded by the RASSF1 gene, 
which is expressed through alternative splicing to generate 
several transcripts, including RASSF1A (Dammann et al. 
2003). Functional characterizations of RASSF1A showed 
that the protein is associated with microtubules, and plays 
an important role in the stabilization of microtubule during 
different phases of the cell cycle (Dammann et al. 2003, 
2005; Donninger et al. 2007; Richter et al. 2009). Other 
than interaction with microtubule, RASSF1A was reported 
to interact with RAS family members, particularly K-Ras, 
through its conserved Ras association domain (Donninger 
et al. 2007). The interaction suggests that RASSF1A could 
be the down-stream effector of Ras. Since over-expressed 
K-Ras was reported to possess pro-apoptotic activity, it was 
speculated that the pro-apoptotic activity of Ras might be 
associated with RASSF1A (Donninger et al. 2007). In fact, 
over-expression of RASSF1A was shown to elicit apop-
totic responses in cancer cells, and RASSF1A knocked-out 
mice exhibited increased tumorigenesis when challenged 
by chemical carcinogens, confirming the tumor suppressor 
function of RASSF1A (Baksh et al. 2005; Tommasi et al. 
2005; Donninger et al. 2007; Foley et al. 2008).
Interestingly, the pro-apoptotic function of RASSF1A 
was reported to be mediated through interaction with MST-
1/2 kinases, which was shown to play an important role in 
apoptotic signaling through the Hippo signaling pathway 
(Donninger et al. 2007). RASSF1A expression was reported 
to be lost in many cancer cells due to hyper-methylation 
of its promoter (Pfeifer and Dammann 2005; Richter et al. 
2009; Ghazaleh et al. 2010; Dittfeld et al. 2012). Similarly, 
MOAP-1 expression was reported to be low or negative in 
many types of human tumors examined and the contributing 
factors have not been identified (Law et al. 2012; Pang et al. 
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2018). In addition, functional inactivation of Bax has been 
reported due to mutations in the Bax gene found in colorec-
tal, and gastrointestinal tumor cells (Rampino et al. 1997; 
Gil et al. 1999; Yamamoto et al. 1999). Loss of RASSF1A, 
MOAP-1, and Bax functions are likely to create favour-
able conditions for increased tumorigenesis and chemo-
resistance, mainly due to defects in the apoptotic signaling 
mechanism or tumor suppressor function.
To reconstruct the apoptotic signaling pathway involv-
ing MOAP-1, RASSF1A, and Bax that might be missing or 
defective in cancer and drug resistant cancer cells, we sought 
to express MOAP-1, Bax, and RASSF1A (MBR) through an 
IRES based tricistronic expression vector and to examine 
the effects of MBR expression in cancer and drug resist-
ant cancer cells as well as the growth of tumors in mouse 
xenograft model. Our results showed that the expression of 
MBR induces significant impact on chemo-sensitization, the 
growth of cancer and tumor cells as well as chemo-sensiti-
zation that is dependent on the BH3L domain of MOAP-1.
Materials and methods
Cells and reagents
MCF-7 and 293 T cell lines were obtained from ATCC and 
maintained in DMEM media supplemented with 10% fetal 
bovine serum and Penicillin–Streptomycin (Gibco, USA). 
MCF-7-CR (Cisplatin resistant MCF-7) and BMET05 
(patient derived TNBC) cancer cell lines were generous gifts 
from Dr. Hoi-Ling Seng (Sunway University) and Dr. Jann 
Sarkaria (Mayo Clinic, Rochester, Minnesota), respectively. 
The cell lines were similarly maintained in the DMEM 
media containing cell culture supplements. The cDNA 
clones, Bcl-xL and RASSF1a were cloned in pXJ-Myc- or 
HA-tagged vector, which were generous gifts from Dr. Vic-
tor Yu (National University of Singapore). The pTrident vec-
tor was a generous gift from Dr. Marc Folcher (ETH Zürich, 
Switzerland). The pcDNA3.1 (−) vector was obtained from 
Thermo Fisher Scientific (USA). The monoclonal antibod-
ies, MOAP-1 (A11), RASSF1A (3F3) and Bax (6A7), were 
obtained from Santa Cruz Biotechnology, USA.
Generation of MBR and MBRX tricistronic expression 
constructs
For generation of MBR (MOAP-1, Bax, and RASSF1A) 
and MBRX (MOAP-1ΔBH3L, Bax, and RASSF1A) tri-
cistronic expression cassettes in pcDNA 3.1 (−), MOAP-1 
and MOAP-1ΔBH3L were PCR amplified from pXJ-HA-
MOAP-1 or pXJ-Myc-MOAP-1ΔBH3L using forward and 
reverse primers containing Bam HI and Hind III restric-
tion sites, respectively. The PCR product was gel purified 
followed by digestion with Bam HI and Hind III before 
ligating to a pcDNA 3.1 (−) vector containing gene expres-
sion cassette consisting of IRES 1-Bax-IRES 2-RASSF1A, 
which was released from a pTrident vector (Fussenegger 
et al. 1998; Moser et al. 2000). The pcDNA-HA-MBR and 
pcDNA-Myc-MBRX expression cassettes were subsequently 
sub-cloned into pXJ vector to generate pXJ-HA-MBR and 
pXJ-Myc-MBRX, respectively. Expression constructs 
encoding Bcl-xL, Bax, MOAP-1, MOAP-1ΔBH3L and 
RASSF1A were also generated in pXJ vector. The sequence 
identities of all expression constructs were confirmed by 
sequencing. The expression constructs encoding human 
genes were used in the transfection experiments except 
where indicated otherwise.
Gene reporter Luciferase assay
MCF-7 and MCF-7-CR cells were seeded in 24-well plate 
and transfected with a total of 2.1 µg of total DNA per well, 
consisting of increasing quantity of MBR expression cassette 
or the indicated expression construct, with 0.5 µg of firefly 
luciferase reporter gene. All transient transfection experi-
ments were carried out using pXJ-HA-MBR expression cas-
sette or expression clone encoded in pXJ vector unless stated 
otherwise. Empty plasmid vector was used to equalize the 
total DNA amount in each of the transfection reactions. The 
expression constructs were mixed with PEI (Polysciences, 
USA) and incubated for 10 min at room temperature prior to 
transfection. DNA-PEI mixtures were added to 24-well plate 
in drop wise manner and incubated overnight in a 37 °C 
 CO2 incubator followed by incubation with anti-cancer drug 
for 16–24 h where indicated and subsequently lysed with 
RIPA lysis buffer and assayed with One-Glo ™ Luciferase 
Assay System (Promega, USA) according to manufactur-
er’s protocol. Remaining lysates were assayed with Pierce 
BCA Protein Assay Kit (Thermo Fisher Scientific, USA) to 
determine protein concentration for normalization of firefly 
Luciferase activity. Readings from Plate Reader Infinite 200 
PRO (Tecan Trading AG, Switzerland) were tabulated and 
expressed as relative percent cell viability after normaliza-
tion with vector transfected cells which was assigned as 
100% cell viability.
Gene reporter GFP‑Luciferase assay
MCF-7 and BMET05 cancer cells were seeded in a 24-well 
plate (2 × 105 cells per well) and transiently transfected 
(Lipofectamine 3000, Invitrogen) with increasing doses 
up to 0.8 µg of the pXJ-HA-MBR expression cassette, 
together with 0.1 µg of lentiviral vector encoding for green 
fluorescence protein and firefly luciferase (LV-GFP-Fluc). 
After18 h, transfected cells were transferred to the wells 
of a 96-well plate in triplicates, and treated with 400 ng/
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µL of cisplatin 8 h later. After 24 h, post-treatment cul-
ture medium was aspirated, 100 µg/mL of D-luciferin was 
added to the plate and incubated for 5 min. Biolumines-
cence signal was measured using a Promega Biolumines-
cence plate reader. The percentage of cell viability was 
normalized using the empty vector transfected cells as 
100%.
Co‑immunoprecipitation
293 T cells were transiently co-transfected with 10 µg each 
of the indicated expression constructs using PEI (Poly-
sciences, USA) transfection reagent in the serum free media. 
After 6 h, the transfected cells were incubated in fresh media 
containing 10% serum for 48 h before the cells were sus-
pended in lysis buffer (20 mM Tris, pH 7.5, 150 mM NaCl, 
0.2% Nonidet P-40, 1  mM EDTA) containing protease 
inhibitors. The cell lysates were incubated on ice for 30 min 
and vortexed. The cell lysates were centrifuged at 12,000 
×g for 20 min at 4 °C. The supernatants were normalized 
for protein concentration and equal amounts of the super-
natant were incubated with antibody for 2 h at 4 °C fol-
lowed by incubation with protein-A agarose overnight. The 
immunoprecipitates were centrifuged and washed 5 times 
before mixing with protein loading buffer and boiled for 
5 min followed by centrifugation. The supernatant contain-
ing the immunoprecipitates were resolved by SDS-PAGE 
and analyzed on Western blot with the indicated antibody.
Western blot analysis
293 T cells were seeded in 100 mm plate and transfected 
with 10 µg of pXJ-HA-MBR expression cassette or vector 
overnight in a 37 °C  CO2 incubator. Cells were subsequently 
harvested and centrifuged. Cell pellet was washed once with 
1X PBS prior to lysis with RIPA lysis buffer. Lysate was 
passed through a 21-gauge needle 10 times for complete 
lysis and centrifuged. The protein concentration in the 
supernatant was quantified through BCA protein assay kit 
(Thermo Fisher Scientific, USA). Aliquots (40 µg) of lysate 
were loaded equally in each well and resolved in 12% SDS-
PAGE followed by electro-blotting onto nitrocellulose mem-
brane. The membrane was blocked in 5% Blotto for 1 h fol-
lowed by incubation with MOAP-1 (A11), RASSF1A (3F3) 
or Bax (6A7) mouse monoclonal antibodies. The membrane 
was subsequently incubated with goat anti-mouse secondary 
antibody conjugated with HRP (Invitrogen, USA). Signals 
were developed with SuperSignal™ West Femto Maximum 
Sensitivity Substrate (Thermo Scientific, USA) and image 
was captured with ImageQuant ™ LAS 500 (GE Healthcare, 
USA).
Flow cytometry
MCF-7 cells were seeded in 6-well plate and co-transfected 
with 1 µg of pcDNA-HA-MBR expression cassette or 1 µg 
of Bcl-xL expression construct together with 0.5 µg of GFP 
reporter gene followed by incubation in a 37 °C  CO2 incu-
bator overnight. Cells were collected through trypsinization 
and washed once with 1X PBS prior to resuspension in 1X 
Annexin V Binding Buffer (BD Biosciences, USA). Cells 
were then stained with 5 µL of Annexin V conjugated with 
APC (BD Biosciences, USA) and 2 µL of Propidium Iodide 
(PI, Nacalai Tesque, Japan) for 15 min in the dark at room 
temperature. After 15 min of incubation, Annexin-V and PI 
positive cells were analysed with BD FACS Calibur™ (BD 
Biosciences, USA).
Stable clone selection and cell viability assay
MCF-7 cells were seeded in 60 mm cell culture plate and 
transfected with 1 µg of pcDNA-HA-MBR, pcDNA-Myc-
MBRX expression cassette or 1 µg of pcDNA vector over-
night. After transfection, stable clones were selected with 
Geneticin Sulfate (800 µg/ml, Santa Cruz, USA) for 1 week 
and maintained with Geneticin Sulfate (400 µg/ml, Santa 
Cruz, USA) for two weeks. Stable clone colonies were 
washed once with 1X PBS prior to staining with 4% Crystal 
Violet-Methanol solution for 10 min. The plates were gently 
rinsed with water to remove excess stain and air-dried before 
image was captured. The stable clone colonies were counted 
and the number of stable clones from vector transfected cells 
was assigned 100%. Furthermore, individual stable clone 
colonies were isolated from MCF-7 cells transfected with 
each expression construct. Representative stable clones 
were further expanded for subsequent studies. To measure 
chemo-sensitivity of stable clones, the cells were seeded in 
96-well plate at 70% confluency in the presence of 400 µg/
ml G418 followed by treatment with different concentra-
tions of Etoposide or Cisplatin for 24 h. Cell viability of the 
treated cells was measured using MTT reagent.
Real time PCR
293 T cells were seeded in a 6-well plate and transfected 
with 1 µg of pXJ-HA-MBR expression cassette or vector. 
After transfection, total RNA was extracted with easy-BLUE 
Total RNA Extraction Kit (iNtRON Biotechnology, Korea) 
and converted into cDNA with SuperScript™ III Reverse 
Transcriptase (Invitrogen, USA). The concentration of 
cDNA was quantified with Biodrop (Biodrop, UK) and nor-
malized prior to real time PCR analysis. Master mix was 
prepared with SsoAdvanced ™ Universal SYBR® Green 
Supermix (Bio-Rad, USA) for the PCR reactions and each 
PCR reaction was carried out in triplicates in the microtube 
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with the indicated primers: Actin ( +) 5′- GGA CTT CGA 
GCA AGA GAT GG-3′, Actin (−) 5′-AGC ACT GTG 
TTG GCG TAC AG-3′, MOAP-1 ( +) 5′- TGT TGG CAC 
AGG CAT TAG-3′, MOAP-1 (−) 5′-TCC AGC GTC CAA 
ATT CTT C-3′, mBax ( +) 5′- CTG ACC TTG GAG CAG 
CCG-3′, mBax (−) 5′-GCT CGG GCA CTT TAG TGC-3′, 
RASSF1A ( +) 5′- TGG GAG ACA CCT GAC CTT TC-3′, 
RASSF1A (−) 5′- TGG GCA GGT AAA AGG AAG TG-3′. 
PCR reactions were carried out in CFX 96™ Real Time 
PCR machine and the data were analysed with CFX Man-
ager™ Software (Bio-Rad, USA). The data were normalized 
against data from Actin. Small aliquots of the PCR reactions 
were analysed through agarose gel electrophoresis.
Nuclei condensation assay
MCF-7 cells seeded on sterile glass coverslip at 70–80% 
confluency in 6-well plate were transfected with 1.5 µg of 
the indicated pXJ-expression construct, together with 1.5 µg 
of GFP reporter gene construct for 18 h. The cells were fixed 
with 2% paraformaldehyde, and stained with DAPI, followed 
by Fluorescence Microscopy using Nikon Fluorescence 
Microscope. Percent condensed nuclei was calculated based 
on the average of condensed nuclei counted in each of the 
five randomly chosen fields divided by the total number of 
nuclei counted in each field.
Spheroid cancer model
MCF-7 cells were stably transfected with pcDNA vector 
or pcDNA-HA-MBR and the stable clones were seeded in 
Nunclon™ Sphera™ Microplates (Thermofisher, USA) at 
2.5 × 103 cells per well and incubated at 37 °C for 72 h to 
allow the formation of spheroids. The spheroids were sub-
sequently treated with different concentrations of Cisplatin 
for 24 h. The cell viability of the spheroid cells was meas-
ured in triplicates using Alamar blue assay in which 20 µl of 
Alamar Blue reagent were added to each spheroid per well in 
triplicate, followed by incubation at 37 °C for 4 h. The fluo-
rescence signals were recorded by Tecan microplate reader. 
Relative percent cell viability was obtained after normali-
zation of the fluorescence readings against the fluorescence 
readings of the untreated spheroids. The caspase activity of 
the spheroids was measured in triplicates using Caspase-3 
Activity Assay Kit (Cell Signaling Technology, USA) 
accordingly to the manufacture’s instruction. Fluorescence 
reading was obtained using the Tecan microplate reader.
Mouse xenograft model
Xenograft experiments were performed as previously pub-
lished (Ponnusamy et al. 2019). In brief, two million of 
MCF-7 cells consisting of pcDNA-HA-MBR or pcDNA 
stable clones, corresponding to MBR-Sc and V-Sc, were 
injected with 50% Matrigel under the mammary fat pad in 10 
female NOD SCID Gamma (NSG) mice in accordance with 
the IACUC approved protocol. In addition, 17β-Estradiol 
(1.7 mg) 60-day slow release pellet (Cat # SE-121, Innova-
tive research of America, Inc.) was implanted subcutane-
ously in each mouse on the same day the mice were xeno-
grafted with the stable clones. Tumor volume was measured 
twice weekly and the volume was calculated using the for-
mula length ×  width ×  width × 0.5236. At the end of the 
study (total of 24 days), animals were sacrificed and tumors 
were excised and weighed.
TUNEL staining of tumor tissues
Tumors obtained from the mouse xenograft model were pro-
cessed by HistoWiz (USA) for TUNEL staining using Dea-
dend™ colorimetric TUNEL system (Promega, USA). The 
tissues were embedded in paraffin, sectioned at 4 µm and 
processed for TUNEL staining according to the manufactur-
ers’ instruction. The TUNEL positive cells were quantified 
from six randomly selected fields of representative tumor 
sections using ImageJ software (Schneider et al. 2012).
Statistical analysis of data
Data obtained from at least three replicate measurements 
were subjected to statistical analysis. ANOVA test was per-
formed to determine whether the observed differences in the 
data were statistical significant as indicated by the p-value 
(p) where p < 0.05 or p < 0.001 was considered as statistical 
significance.
Results
To reconstruct the cell signaling pathway involving 
MOAP-1, Bax, and RASSF1A (MBR), the cDNAs encod-
ing the individual proteins were PCR amplified, and sub-
cloned into the pTrident vector containing IRES 1 and 
IRES 2 sequences, and further sub-cloned into pXJ and 
pcDNA vectors to generate MBR tricistronic expression 
cassette for constitutive expression of MBR driven by the 
CMV promoter (Fig. 1a). Expression of the individual 
proteins encoded by MBR was further analysed through 
Western blot. Over-expressed HA-tagged MOAP-1 from 
the MBR expression cassette was identified using the anti-
MOAP-1 antibody (Fig. 1b). Similarly, over-expressed 
RASSF1A and Bax from the MBR expression cassette 
were identified using anti-RASSF1A or anti-Bax antibody, 
respectively (Fig. 1b). To quantitatively measure MBR 
expression, reverse-transcription PCR (RT-PCR) was 
carried out with RNA isolated from the MBR transfected 
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293 T cells, and the results showed that exogenous MOAP-
1, Bax, and RASSF1A encoded by MBR expression cas-
sette were highly expressed in transfected 293 T cells 
(Fig. 1c, d).
To investigate whether expression of MBR induced 
chemo-sensitization in cancer cells, MCF-7 cells were tran-
siently co-transfected with the MBR expression cassette and 
GFP reporter gene followed by Etoposide treatment. The 
GFP positive cells were examined and the data showed that 
MBR potently induced chemo-sensitization of transfected 
MCF-7 cells, resulting in nuclei condensation, a classi-
cal hallmark of apoptosis (Fig. 2a, b). To further examine 
the impact of MBR mediated chemo-sensitization, MCF-7 
cells were transiently transfected with increasing quantity of 
MBR expression cassette followed by Cisplatin treatment. 
Chemo-sensitization mediated by MBR was subsequently 
measured through reporter gene assay and the data showed 
that MBR mediated dose-dependent apoptosis, leading to 
about 40% reduction in cell viability which was statistically 
significant when the MCF-7 cells were transfected with the 
highest quantity (0.8 µg) of MBR expression construct in the 
presence of Cisplatin treatment (Fig. 2c).
Cancer cells are known to develop chemo-drug resist-
ance through multiple mechanisms, rendering existing 
chemo-drugs ineffective for cancer treatment or signifi-
cant higher doses of chemo-drugs are required to achieve 
therapeutic outcome (Luqmani 2005; d ‘Amato et al. 2007; 
Raguz and Yagüe 2008; Pan et al. 2016). Furthermore, 
chemo-drug resistant cancer cells are known to metasta-
size to other tissues after chemo-drug treatments (Kara-
giannis et  al. 2017). To examine whether chemo-drug 
resistant cancer cells are responsive to apoptosis signal-
ing mediated by MBR, Cisplatin-resistant MCR-7 cells, 
MCF-7-CR, and MCF-7 cells were transiently transfected 
with MBR followed by Cisplatin treatment. MCF-7-CR 
cells showed high level of resistance to Cisplatin treatment 
when compared to MCF-7 cells (Fig. 3a). When treated 
with increasing concentrations of Cisplatin (0–160 μM), 
the cell viability of MCF-7-CR and MCF-7 cells decreased 
dose-dependently to 31%, and 7%, respectively (Fig. 3a). 
To examine whether MBR expression could promote 
chemo-sensitivity of MCF-7-CR cells when treated with 
Cisplatin, MCF-7 and MCF-7-CR cells were transfected 
with increasing quantity of MBR expression cassette 
Fig. 1  Schematic representation and expression analysis of Tri-
cistronic expression cassette, MBR. a Schematic representation of 
MBR expression cassette encoding HA-tagged MOAP1, Bax, and 
RASSF1A. b Western Blot analysis of MBR expression. 293T cells 
were transiently transfected with pXJ-HA-MBR expression cas-
sette and cell lysate of transfected cells was prepared for SDS-PAGE 
and Western blot detection with anti-MOAP-1, anti-Bax and anti-
RASSF1A antibodies.  c Real-Time PCR analysis of MBR expres-
sion.  293T cells were transiently transfected with pXJ-HA-MBR 
expression cassette followed by RNA extraction and the extracted 
RNA was used as starting material for reverse transcription-based 
PCR (RT-PCR) with respective gene specific primers. For RT-PCR 
analysis of Bax, mouse Bax (mBax) specific PCR primers were used. 
PCR amplified products were analysed in agarose gel. d Quantifica-
tion of mRNA transcripts. RT-PCR was performed as described in c, 
and mRNA transcripts were quantified and normalized against Actin 
mRNA
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followed by treatment with Cisplatin (160 μM). As shown 
in Fig. 3b, transient expression of MBR expression cassette 
in MCF-7 and MCF-7-CR cells promoted dose-dependent 
chemo-sensitization of MCF-7 and MCF-7-CR cells. The 
cell viability of MCF-7-CR cells further decreased to 15% 
when transfected with MBR expression cassette followed 
by Cisplatin treatment (Fig. 3c).
To further investigate whether chemo-sensitization medi-
ated by MBR is effective against chemo-drug resistant tri-
ple negative breast cancer cells (TNBC), BMET05 cancer 
cells, which are primary human cancer cells isolated from 
the breast tumor of a cancer patient with clinical history of 
metastatic breast cancer accompanied by brain metastases, 
were transiently transfected with the MBR expression cas-
sette followed by Cisplatin treatment and the results showed 
that MBR mediated dose-dependent chemo-sensitization 
of BMET05 cancer cells, resulting in approximately 40% 
reduction of cell viability (Fig. 3d), this is consistent with 
the data obtained from MBR mediated chemo-sensitization 
of MCF-7-CR cells. The results thus lend further support to 
the effectiveness of chemo-sensitivity mediated by MBR for 
the treatment of clinically relevant cancer, including triple 
negative breast cancer.
For further characterization of MBR, the expression 
cassette encoding MBR was transiently transfected into 
MCF-7 cells, and cell viability of the transfected cells 
was measured through flow cytometry. As shown in 
Fig. 4, transient transfection of MCF-7 cells with MBR 
expression cassette induced apoptosis, leading to genera-
tion of Annexin-V positive cells (Fig. 4a, upper and lower 
panels). To overcome the limitations of transient trans-
fection, including relatively poor transfection efficiency, 
stable clones expressing MBR were generated in MCF-7 
cells (herein referred to as MBR-Sc) and the data showed 
that the expression of MBR inhibited the growth of MBR-
Sc, resulting in 86% reduction in the number of MBR-Sc 
generated when compared to the stable clones generated 
from vector (herein referred to as V-Sc) transfected cells, 
suggesting that MBR inhibits long-term survival of cancer 
cells (Fig. 4b, upper and lower panels). To further substan-
tiate the role of MBR in apoptosis signaling, spheroids, 
which were reported to maintain cellular characteristics 
Fig. 2  Transient expression of MBR promotes chemo-sensitization of 
Etoposide and Cisplatin treated MCF-7 cells. a Transient expression 
of MBR induced chemo-sensitization of Etoposide treated MCF-7 
cells. pXJ-HA-MBR expression cassette was transiently co-trans-
fected with the GFP expression construct into MCF-7 cells followed 
by Etoposide treatment. The MCF-7 cells were subsequently stained 
with DAPI and processed for fluorescence microscopy. Arrows indi-
cate GFP-positive cells with condensed nuclei. b Quantification of 
MBR transfected MCF-7 cells with condensed nuclei. MCF-7 cells 
were transfected as described in a, and percent condensed nuclei of 
transfected cells were determined by counting GFP-positive cells 
from five randomly chosen fields under the microscope. c Transient 
expression of MBR induced dose-dependent chemo-sensitization 
of Cisplatin treated MCF-7 cells. MCF-7 cells were transiently co-
transfected with increasing quantity of pXJ-HA-MBR expression cas-
sette, together with expression construct encoding GFP and Firefly 
Luciferase genes followed by Cisplatin treatment. Relative percent 
cell viability of transfected cells was determined based on measured 
Luciferase activity as described in “Materials and methods” section
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similar to tumor cells (Grill et al. 2002; Weiswald et al. 
2015; Langhans 2018), were prepared from MBR-Sc and 
V-Sc to facilitate further characterization of the func-
tional role of MBR in apoptosis signaling. The spheroids 
were treated with increasing concentration of Cisplatin. 
Although the spheroids were prepared from the same num-
ber of cells, the MBR-Sc spheroids were smaller in size 
when compared to the V-Sc spheroids (Fig. 5a). Further-
more, the MBR-Sc spheroids exhibited enhanced chemo-
sensitivity when treated with increasing concentration of 
Cisplatin, resulting in low cell viability and an increase 
in apoptosis with a dose-dependent increase in Caspase 3 
activity when compared to V-Sc spheroids (Fig. 5b, left 
and right panels), suggesting MBR plays an important role 
in the activation of apoptotic signaling in the MBR-Sc 
spheroids.
To evaluate potential impacts of MBR expression in 
cancer cells in vivo, MBR-Sc and V-Sc were xenografted 
separately into the NSG female mice in the presence of 
17β-estradiol, an estrogen receptor (ER) ligand that is known 
to stimulate ER mediated cell signaling and cell proliferation 
of ER positive cells, including MCF-7 cells which were used 
to generate the MBR-Sc and V-Sc. NSG mice xenografted 
with V-Sc formed large tumors (Fig. 5c, d). In contrast, 
the tumors generated from MBR-Sc in NSG mice showed 
growth retardation with an average tumor volume and weight 
Fig. 3  Transient expression of MBR promotes chemo-sensitization 
of Chemo-drug resistant cancer cells. a Cisplatin-resistant MCF-7 
cells (MCF-7-CR), exhibited chemo-resistance to Cisplatin. MCF-7 
and MCF-7-CR cells were transfected with vector (1.6 µg) and 
Luciferase reporter (0.5 µg) gene followed by treatment with various 
doses of Cisplatin. Relative percent cell viability was quantified as 
described in “Materials and methods” section. b Expression of MBR 
promoted dose-dependent chemo-sensitization of MCF-7-CR cancer 
cells. MCF-7 and MCF-7-CR cells were transiently co-transfected 
with increasing quantity of pXJ-HA-MBR expression cassette and 
Luciferase reporter gene followed by treatment with Cisplatin (160 
μM). Relative percent cell viability was determined as described in 
a. c Expression of MBR enhanced chemo-sensitization of Cisplatin-
resistant cancer cells to Cisplatin treatment. MCF-7 and MCF-7-CR 
cells were treated with Cisplatin (160 μM) or transfected with 800ng 
of MBR expression cassette followed by Cisplatin treatment (160 
μM) as described in a, b where the data were re-plotted to highlight 
chemo-sensitivity of MCF-7-CR cells toward Cisplatin in the pres-
ence of MBR. d MBR induced dose-dependent chemo-sensitization 
of BMET05 cancer cells when treated with Cisplatin. BMET05 can-
cer cells were transiently co-transfected with increasing quantity of 
pXJ-HA-MBR and expression construct encoding GFP and Lucif-
erase genes followed by treatment with Cisplatin. Relative percent 
cell viability was determined as described in “Materials and meth-
ods” section
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approximately 20 X and 32 X smaller than the tumors gener-
ated from V-Sc (Fig. 5c, d), respectively, indicating that the 
expression of MBR in the cancer cells exerts strong inhibi-
tory impact on the growth of MBR expressing tumor cells 
in vivo. Furthermore, the tumor cells generated from the 
MBR-Sc exhibited extensive apoptotic cell death, resulting 
in 3-5X more TUNEL positive cells when compared to the 
tumor cells generated from V-Sc (Fig. 5e).
The BH3-like (BH3L) domain of MOAP-1 has been 
reported to play an important role in pro-apoptotic signal-
ing mediated by MOAP-1 as it interacts and promotes Bax 
activation (Tan et al. 2001, 2005; Baksh et al. 2005; Foley 
et al. 2008; Law et al. 2015). However, its function has not 
been established in the presence of cell signaling mediated 
by MBR, including whether the BH3L domain of MOAP-1 
is required for MBR mediated chemo-sensitization. To deter-
mine the functional role of BH3L domain of MOAP-1 in 
MBR mediated cell signaling, a MOAP-1ΔBH3L mutant 
was generated. Increasing quantity of expression construct 
encoding MOAP-1ΔBH3L mutant was co-transfected with 
MBR expression construct into MCF-7 cells, and the results 
showed that MOAP-1ΔBH3L dose-dependently inhibited 
MBR mediated apoptosis signaling (Fig. 6a). Over-expres-
sion of Bcl-XL, a pro-life member of Bcl-2 family which is 
known to bind Bax, similarly antagonized apoptotic activity 
of MBR (Fig. 6a). To further examine the impact of MBR 
and the role of BH3L domain of MOAP-1 on mediating 
chemo-sensitization, stable clones of MBR (MBR-Sc) 
and MBRX (MBRX-Sc) were generated in MCF-7 cells 
and treated with chemo-drugs. MBR-Sc showed the high-
est sensitivity to chemo-drugs in which the cell viability 
of Cisplatin treated cells decreased dose-dependently while 
the MBRX-Sc showed the highest resistance to Cisplatin 
when compared to V-Sc, suggesting that apoptosis signal-
ing mediated by MBR is dependent on the BH3L domain of 
MOAP-1 (Fig. 6b, left panel). Similar results were obtained 
Fig. 4  Expression of MBR promotes apoptosis and inhibits growth of 
MCF-7 stable clones. a Expression of MBR induced apoptosis sig-
nalling in MCF-7 cells. MCF-7 cells were transiently transfected with 
pcDNA-HA-MBR expression cassette together with GFP reporter 
gene followed by staining with Annexin-V and Propidium Iodide (PI). 
GFP positive cells were sorted by the flow cytometer and analyzed to 
identify PI and Annexin-V positive cells. Upper panel: Flow Cytome-
try analysis of PI and Annexin V positive cells. Lower panel, quantifi-
cation of Annexin V positive cells from the data obtained through the 
flow cytometry analysis. b Expression of MBR reduced the number 
of MCF-7 stable clones. MCF-7 cells were transfected with the vector 
or pcDNA-HA-MBR expression cassette and selected with Geneticin. 
Selected stable clones were stained with crystal violet. Upper panel, 
crystal violet stained stable clones. Lower panel, relative number of 
MBR stable clones compared to stable clones generated from vector 
transfected cells (assigned 100%)
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when the MBR-Sc and MBRX-Sc were treated with Etopo-
side (Fig. 6b, right panel). To examine the mechanism of 
action of MOAP-1ΔBH3L mutant in conferring inhibition 
of MBR mediated apoptosis and chemo-sensitization, co-
immunoprecipitation studies of MOAP-1ΔBH3L mutant 
with MOAP-1, Bax, or RASSF1A were carried out to deter-
mine potential protein interaction of MOAP-1ΔBH3L with 
each of the protein components of MBR. The results indicate 
that while MOAP-1 interacted with Bax, MOAP-1ΔBH3L 
failed to do so (Fig. 6c) and it is consistent with the report 
that the BH3L domain of MOAP-1 is required for interac-
tion with Bax (Tan et al. 2001). However, to investigate how 
MOAP-1ΔBH3L antagonizes MBR induced apoptosis and 
rendering MBRX resistant to chemo-drugs, expression con-
structs encoding MOAP-1ΔBH3L and MOAP-1 were tran-
siently co-transfected with MOAP-1 or RASSF1A expres-
sion construct in 293 T cells for co-immunoprecipitation 
studies and the results showed that while MOAP-1ΔBH3L is 
unable to interact with Bax, it is functionally active by inter-
acting with RASSF1A (Fig. 6d), suggesting that MOAP-
1ΔBH3L antagonizes MBR mediated apoptosis through 
competitive binding to RASSF1A and rendering MBRX 
functionally inactive due to sequestering of RASSF1A by 
MOAP-1ΔBH3L mutant (Fig. 7). 
Discussion
Cancer chemo-therapies are often met with tough chal-
lenges due to the relative toxic nature of small molecule 
drugs and chemo-resistance of cancer cells (Chatelut et al. 
2003; Vergès et al. 2014). Based on our current understand-
ing of chemo-resistance, tumor cells acquire multiple muta-
tions, and are genetically heterogeneous (Meacham and 
Fig. 5  MBR stable clone exhibits enhanced chemo-sensitization in 
spheroid model and tumor growth retardation in 17β-estradiol stimu-
lated mouse xenograft model. a Morphology of MCF-7 spheroids 
derived from MBR-Sc and V-Sc. The MBR-Sc and V-Sc were cul-
tured in low cell attachment microplate and treated with increasing 
concentration of Cisplatin as described in “Materials and methods” 
section. b Spheroids derived from the MBR-Sc showed enhanced 
chemo-sensitization with increase in apoptotic cell death. The MBR-
Sc and V-Sc spheroids were treated with Cisplatin as described in a, 
followed by quantitative measurements of spheroid cell viability and 
caspase activity. Cell Viability was quantified with Alamar Blue and 
normalized against the readings from untreated spheroids. Caspase 
3 activity of the spheroids was measured and normalized against the 
control spheroids without treatment. c Growth retardation of tumors 
generated from MBR-Sc in17β-estradiol stimulated mouse xeno-
graft model. The V-Sc and MBR-Sc cells were injected in NSG mice 
stimulated with 17β-estradiol slow release pellet and the tumors 
were excised from the mice 24 days later. d The volume and weight 
of MBR-Sc tumors were much smaller than the V-Sc tumors. The 
volume and weight of the V-Sc and MBR-Sc tumors were measured 
as described in “Materials and methods” section. e MBR-Sc tumors 
showed increase in apoptotic cell death. The V-Sc and MBR-Sc 
tumors, which were labelled as vector and MBR-T1-3, respectively, 
were sectioned (4 µm) for TUNEL staining and TUNEL positive cells 
were quantified as descried in “Materials and methods” section
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Morrison 2013; Eun et al. 2017; Prasetyanti and Medema 
2017). Although multiple mechanisms could potentially con-
tribute to chemo-resistance, cell death inhibition through 
inactivation of tumor suppressors, and pro-apoptotic genes 
is likely to play a major role in chemo-resistance (Cotter 
2009; Jones and Thompson 2009). The DNA promoter 
of tumor suppressor protein, RASSF1A, was found to be 
hyper-methylated, leading to silencing of its gene expres-
sion (Pfeifer and Dammann 2005; Richter et al. 2009; Ghaz-
aleh et al. 2010; Dittfeld et al. 2012). Similarly, MOAP-
1, another tumor suppressor, that links to RASSF1A, was 
found to be tightly regulated through the ubiquitin–protea-
some pathway, and its expression was low or undetectable 
in twenty types of tumor cells (Fu et al. 2007; Law et al. 
2012). To examine whether physiologically relevant signal-
ing molecules could be co-expressed to enhance or promote 
apoptotic signaling pathway in cancer and drug-resistant 
cancer cells, tricistronic expression cassette that expressed 
MOAP-1, Bax, and RASSF1A (MBR) was generated and 
was shown to mediate apoptosis potently, leading to high 
levels of apoptotic cell death when transfected into MCF-7 
cells alone or with chemo-drug treatments. Furthermore, it 
is interesting to know that MBR induced apoptotic cell death 
and chemo-sensitization of MCF-7 and MCF-7-CR cells in 
a dose dependent manner in the presence of Cisplatin. The 
potency of MBR was further demonstrated through genera-
tion of MBR-Sc in MCF-7 cells, in which fewer than 14% 
of the MBR-Sc cells exhibited long term survival, provid-
ing further evidence to support the potent effect of MBR in 
mediating apoptosis signaling in cancer cells. In addition, 
the data obtained from MBR-Sc spheroids highlight that the 
expression of MBR in the spheroid cells promotes chemo-
sensitization through activation of apoptotic signaling by 
activating Caspase 3.
Fig. 6  BH3L domain of MOAP-1 Is required for enhanced chemo-
sensitization mediated by MBR. a MOAP-1 BH3L-mutant dose-
dependently inhibited MBR mediated apoptosis in MCF-7 cells. 
Increasing quantity of expression construct encoding pXJ-Myc-
MOAP-1 BH3L-Mutant (dBH3L) was transiently co-transfected 
with pcDNA-HA-MBR expression construct, together with Lucif-
erase reporter gene. The quantities of transfected expression con-
structs in MCF-7 cells were indicated in brackets (1×, 400 ng; 3×, 
1200  ng). Cell viability was determined as described in “Materi-
als and methods” section. b MBR-Sc exhibited enhanced chemo-
sensitivity while MBRX-Sc showed chemo-drug resistance when 
treated with Cisplatin. The stable clones were treated with different 
concertation of Cisplatin and Etoposide for 24 h and cell viability 
was measured as described in “Materials and methods” section. c 
MOAP-1 BH3L-mutant failed to interact with Bax. Expression con-
structs encoding HA-tagged Bax and the indicated Myc-tagged pro-
tein were transiently co-transfected into 293T cells and cell lysates of 
the transfected cells were prepared for co-immunoprecipitation with 
polyclonal antibody against Bax (N20) followed by detection with 
monoclonal anti-Myc antibody on Western blot. d MOAP-1 BH3L-
mutant interacted with RASSF1A. Expression constructs encoding 
the indicated HA- and Myc-tagged proteins were transiently trans-
fected into 293T cells and cell lysates were prepared for co-immuno-
precipitation with monoclonal anti-HA antibody followed by protein 
detection on Western blot with polyclonal anti-Myc antibody
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The findings were further substantiated through mouse 
xenograft studies in which NSG mice xenografted with 
MBR-Sc produced much smaller tumors than the NSG 
mice xenografted with the V-Sc, this is despite the fact that 
both the V-Sc and MBR-Sc xenografted NSG mice were 
under the influence of 17β-estradiol which is known to drive 
the growth of estrogen receptor (ER) positive cancer cells 
(Acconcia and Marino 2011; Dall et al. 2015; Sun et al. 
2015), including MCF-7 cells which the V-Sc and MBR-Sc 
were generated. The full impact of the 17β-estradiol on the 
growth of the V-Sc derived tumor cells in the NSG mice 
was evidenced by the generation of tumors that were much 
bigger than the tumors generated from MBR-Sc. The results 
potentially provide novel insight into the development of 
alternative treatment option for breast cancer by targeting 
the cell signaling pathway mediated by MBR, leading to 
the destruction of the cancer cells through the mitochon-
drial signaling pathway. This confers an advantage over the 
conventional therapies that target the ER receptor through 
ER antagonists, which often fail to work in triple negative 
breast cancer due to lack of ER expression in this type of 
cancer cells. Moreover, it is possible to further enhance the 
effectiveness of MBR mediated cancer therapy by including 
small dose of chemo-drugs to induce chemo-sensitization in 
the cancer cells, which effectively reduces the side-effects 
associated with the chemo-drugs.
Interestingly, MBR induced apoptosis was shown to be 
inhibited dose-dependently by MOAP-1ΔBH3L mutant, 
which lacks the BH3L domain important for Bax association 
and activation. We first hypothesized that the lack of interac-
tion with Bax may be due to structural alteration of MOAP-
1ΔBH3L mutant that leads to generation of a non-functional 
protein. However, our data showed that MOAP-1ΔBH3L is 
not functionally inactive as it interacts with MOAP-1 and 
RASSF1A (Fig. 6d). More importantly, our data showed 
that MOAP-1ΔBH3L antagonizes MBR induced apoptosis 
by binding to RASSF1A, a pro-apoptotic protein reported to 
be required for activation of MOAP-1-Bax signaling path-
way through mitochondria. This data is consistent with the 
reported data which showed that the amino acids 202E KRRR 
of MOAP-1 are required for binding to RASSF1A while 
the BH3L domain (120LSRALGHE) of MOAP-1 is required 
for binding to Bax (Tan et al. 2001; Foley et al. 2008). This 
is the first report that describes the mechanism of action 
of MOAP-1ΔBH3L by interacting with RASSF1A, which 
leads to functional inhibition of MBR-mediated apoptosis 
Fig. 7  Proposed mechanism on the activation of MBR Involv-
ing BH3L domain of MOAP-1. a Activation of MBR. Death stim-
uli promote activation of MBR through activation of MOAP-1 by 
RASSF1A which interacts with MOAP-1. Activated MOAP-1 pro-
motes Bax activation through protein-protein interaction, leading to 
apoptosis signaling mediated by translocation and oligomerization of 
Bax at the mitochondria. b Inhibition of MBRX. MOAP-1ΔBH3L 
interacts with RASSF1A, leading to inhibitions of Bax activation and 
apoptosis signaling mediated by MBRX
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signaling and chemo-resistance of MBRX expressing cancer 
cells.
For effective anti-cancer therapeutics, MBR could poten-
tially be incorporated into viral-mediated gene expression 
system for delivery of MBR to tumor cells, together with 
small molecule anti-cancer drug that promotes apoptotic 
cell death. Induction of apoptosis in tumors was shown to 
play a critical role in remodeling of tumor microenviron-
ment that allows effective penetration of oncolytic virus into 
tumors, leading to efficient killing of tumor cells and reduc-
tion of tumor volume (Nagano et al. 2008; Wong et al. 2010; 
Zeyaullah et al. 2012). Thus, viral mediated gene expression 
of MBR and small molecule drug that promote apoptosis 
synergistically in tumor cells might serve as an alternative 
treatment option for cancer to reduce heavy reliance on small 
molecule anti-cancer drugs, which are known to exert non-
specific, cytotoxic effects to human cells. Future investiga-
tion is required to examine such approach, including the 
influence of tumor microenvironments on MBR-mediated 
apoptosis signaling in tumor cells.
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